دورية أكاديمية
أعرض في EDS

Perception of burden of oral and inhaled corticosteroid adverse effects on asthma-specific quality of life.

التفاصيل البيبلوغرافية
العنوان: Perception of burden of oral and inhaled corticosteroid adverse effects on asthma-specific quality of life.
المؤلفون: Persaud PN; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio., Tran AP; International Consulting Associates, Inc, Arlington, Virginia., Messner D; Center for Medical Technology Policy, Baltimore, Maryland., Thornton JD; The MetroHealth System, Cleveland, Ohio., Williams D; Allergy and Asthma Network, Vienna, Virginia; The University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina., Harper LJ; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio., Tejwani V; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: Tejwanv@ccf.org.
المصدر: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2023 Dec; Vol. 131 (6), pp. 745-751.e11. Date of Electronic Publication: 2023 Aug 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American College of Allergy, Asthma, and Immunology Country of Publication: United States NLM ID: 9503580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4436 (Electronic) Linking ISSN: 10811206 NLM ISO Abbreviation: Ann Allergy Asthma Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: McLean, VA : American College of Allergy, Asthma, and Immunology
مواضيع طبية MeSH: Anti-Asthmatic Agents*/adverse effects , Asthma*/drug therapy , Asthma*/chemically induced , Drug-Related Side Effects and Adverse Reactions*, Humans ; Quality of Life ; Administration, Inhalation ; Adrenal Cortex Hormones/adverse effects ; Weight Gain ; Perception
مستخلص: Background: A multistakeholder core outcome set created for asthma trials showed that asthma-specific quality of life (QoL) was a critically meaningful outcome. However, the definition and measurement methods were undetermined. The adverse effects (AEs) of corticosteroids may be a vital clinical trial outcome. Nevertheless, the AE burden from the patient perspective has not yet been elucidated in an asthma population.
Objective: To characterize patient burden of AEs in oral (OCS) and inhaled corticosteroids (ICS) and how this relates to QoL within an asthma population.
Methods: We used a convergent parallel mixed-methods design with quantitative surveys of known ICS and OCS AEs that were distributed through the Allergy & Asthma Network database, social channels, and the Asthma UK newsletter. Participants rated the AEs that were (1) most burdensome and (2) most desired to be eliminated. Qualitative interviews and focus groups were performed to better understand patient views on barriers reported in the quantitative data, and to identify patient-important barriers that were not a part of the quantitative survey.
Results: The 3 most burdensome AEs for OCS were bone mineral density, infectious complications, and weight gain, whereas weight gain was the most desired to be eliminated. The 3 most burdensome AEs for ICS were pneumonia, hoarse voice, and oral thrush, with concordant results for the most desired to be eliminated. In the focus groups, OCS AEs were concordant with quantitative findings. Focus groups identified unmeasured psychosocial effects, such as embarrassment.
Conclusion: The most burdensome AEs may not be those that would cause patients to stop therapy. Furthermore, qualitative focus groups suggest a psychosocial burden associated with ICS, which needs further investigation.
(Copyright © 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
References: Front Pediatr. 2019 Jun 18;7:246. (PMID: 31275909)
Respir Med. 2014 Mar;108(3):438-44. (PMID: 24462260)
BMJ Open. 2017 Jun 13;7(6):e015245. (PMID: 28615272)
J Pers Med. 2021 Jun 21;11(6):. (PMID: 34205619)
NPJ Prim Care Respir Med. 2015 Jul 09;25:15026. (PMID: 26158805)
Am J Respir Crit Care Med. 2020 Feb 1;201(3):276-293. (PMID: 31525297)
Ann Allergy Asthma Immunol. 2021 Jul;127(1):116-122.e7. (PMID: 33781936)
Pharmaceuticals (Basel). 2010 Mar 08;3(3):514-540. (PMID: 27713266)
Adm Policy Ment Health. 2015 Sep;42(5):533-44. (PMID: 24193818)
Arthritis Rheum. 2006 Jun 15;55(3):420-6. (PMID: 16739208)
Ethn Health. 2022 May;27(4):877-893. (PMID: 32931314)
Allergy. 2006 May;61(5):518-26. (PMID: 16629778)
BMC Fam Pract. 2017 Jan 25;18(1):8. (PMID: 28122492)
Ann Am Thorac Soc. 2021 Nov;18(11):1832-1838. (PMID: 33856968)
J Am Acad Dermatol. 2017 Jan;76(1):1-9. (PMID: 27986132)
Eur Respir Rev. 2021 Jun 23;30(160):. (PMID: 34168063)
Eur Respir J. 2019 Jul 18;54(1):. (PMID: 31048346)
Ann Allergy Asthma Immunol. 2009 Jul;103(1):38-42. (PMID: 19663125)
J Asthma. 2014 Mar;51(2):221-4. (PMID: 24147582)
NPJ Prim Care Respir Med. 2016 Apr 21;26:16017. (PMID: 27098045)
Respir Res. 2017 Jun 26;18(1):129. (PMID: 28651591)
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S88-123. (PMID: 22386511)
J Allergy Clin Immunol. 2009 Jun;123(6):1335-41. (PMID: 19395075)
Calcif Tissue Int. 2006 Sep;79(3):129-37. (PMID: 16969593)
Am J Respir Crit Care Med. 2011 Mar 1;183(5):589-95. (PMID: 20889908)
Mayo Clin Proc. 2012 Sep;87(9):901-4. (PMID: 22958993)
Eur Respir J. 2015 Feb;45(2):396-407. (PMID: 25323234)
Chest. 2013 Dec;144(6):1788-1794. (PMID: 23990003)
Allergy. 2011 Apr;66(4):439-57. (PMID: 21058958)
Respir Med. 2002 Oct;96(10):835-40. (PMID: 12412985)
J Allergy Clin Immunol. 2018 Jan;141(1):110-116.e7. (PMID: 28456623)
معلومات مُعتمدة: P60 MD002265 United States MD NIMHD NIH HHS; U54 MD002265 United States MD NIMHD NIH HHS; UL1 TR002548 United States TR NCATS NIH HHS; UM1 TR004528 United States TR NCATS NIH HHS
المشرفين على المادة: 0 (Anti-Asthmatic Agents)
0 (Adrenal Cortex Hormones)
تواريخ الأحداث: Date Created: 20230829 Date Completed: 20231205 Latest Revision: 20240826
رمز التحديث: 20240827
مُعرف محوري في PubMed: PMC10843134
DOI: 10.1016/j.anai.2023.08.595
PMID: 37643678
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-4436
DOI:10.1016/j.anai.2023.08.595